Of all breast cancer subtypes, immunotherapy is particularly promising for the treatment of TNBC that cannot be treated via hormone therapies due to not expressing commonly targeted hormone receptors—including the ER, PR, and HER2. The gene discussed is NR4A1; the disease is breast carcinoma.